🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Enormous tragedy. Worst in almost 30 years in India. I’m saddened.

2025 Myeloma Treatment Algorithms. #MedTwitter #MyelomaVR

Announcing the Top Post of #EHA25 Day 1 🎉🎉🎉 Coming from our friend Vincent Rajkumar on mSMART risk stratification in #mmsm:

His quiet strength taught me #resilience. His clarity revealed the power of #vision. His humility showed that true #leadership serves others. My father, Qimat Rai Gupta, lives on in every value I uphold. #worldfathersday

For those still questioning why direct care exists — and whether there’s a market for it — here’s your answer: The most valued commodity in healthcare today is access. The patient wants it. The physician wants to give it. And the market is simply responding to that unmet need.

New active substances (NAS) launches at this level correlates with high research output. Note that the celebrated CART for myeloma, cilta-cel, was first developed in China in the Legend-2 trial. pmc.ncbi.nlm.nih.gov/articles/PMC94… LCAR-B38M IQVIA

Great post by David Steensma, MD highlighting the difficulties of treating neoplastic conditions. When a trial is “negative” it’s not the fault of the drug, the trial design, the investigators, or patients. Some cancers and pre cancers are just inherently hard to tackle: